Cargando…
Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications
INTRODUCTION: Repository corticotropin injection (RCI; H.P. Acthar(®) Gel; Mallinckrodt Pharmaceuticals Inc., Hampton, NJ) is a highly purified, prolonged-release porcine preparation of adrenocorticotropic hormone (ACTH) analogue that is FDA-approved for treatment of 19 autoimmune and inflammatory d...
Autores principales: | Philbin, Michael, Niewoehner, John, Wan, George J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565664/ https://www.ncbi.nlm.nih.gov/pubmed/28660550 http://dx.doi.org/10.1007/s12325-017-0569-9 |
Ejemplares similares
-
Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab
por: Knight, Tyler, et al.
Publicado: (2017) -
Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review
por: Girman, Cynthia, et al.
Publicado: (2022) -
Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis
por: Hunter, Samuel F, et al.
Publicado: (2021) -
Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis
por: Busch, Howard, et al.
Publicado: (2022) -
Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis
por: Bindra, Jas, et al.
Publicado: (2021)